Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Biliverdin Reductase A in Chronic Hepatitis C Virus Infection

This study has been completed.
Military University Hospital, Prague
General University Hospital, Prague
Institute for Clinical and Experimental Medicine
Information provided by (Responsible Party):
Iva Subhanova, Charles University, Czech Republic Identifier:
First received: April 23, 2010
Last updated: August 5, 2015
Last verified: August 2015
In this project, the investigators aim to study the role of biliverdin reductase A (BLVRA) in HCV infected patients prior and during/after standard antiviral therapy in association with viral clearance, disease progression and treatment response and in comparison with healthy subjects.

Hepatitis C, Chronic

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Biliverdin Reductase A in Chronic Hepatitis C Virus Infection

Resource links provided by NLM:

Further study details as provided by Iva Subhanova, Charles University, Czech Republic:

Primary Outcome Measures:
  • To assess differences in BLVRA expression in the liver and PBMC in HCV infected patients in responders and non-responders to standard antiviral therapy. [ Time Frame: 72 weeks ]

Secondary Outcome Measures:
  • To analyze the association of genetic polymorphisms of BLVRA with disease progression and treatment response in HCV infected patients. [ Time Frame: 3 years ]

Biospecimen Retention:   Samples With DNA
peripheral blood, liver biopsy

Enrollment: 113
Study Start Date: June 2010
Study Completion Date: June 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
chronic HCV infection
The study was performed on therapeutically naïve patients with chronic HCV infection. Patients with positivity of anti-HCV antibodies, and detectable HCV RNA in serum for at least 6 months, were included in the study.

Detailed Description:
  1. To analyze biliverdin reductase (BLVRA) expression in the liver of HVC infected patients undergoing liver biopsy followed by standard antiviral treatment (peg-interferon plus ribavirin combination therapy) and patients with other forms of liver diseases undergoing liver biopsy as controls.
  2. To analyze BLVRA expression in peripheral blood leukocytes (PBL) of therapeutically naïve HCV patients, during/after standard antiviral therapy and healthy controls.
  3. To analyze BVLRA genetic polymorphisms both in HCV infected patients and healthy controls.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Estimated enrollment: BLVRA expression study: 50 - 100 HCV patients 50 healthy volunteers Polymorphisms of BLVRA study: 300 HCV patients

Inclusion Criteria:

BLVRA expression study

  • Therapeutically naïve HCV patients undergoing antiviral treatment with peg-interferon plus ribavirin combination therapy

BLVRA genetic polymorphisms study

  • HCV infected patients prior, during, after or without antiviral therapy

Exclusion Criteria:

  • Co-infection with HAV, HBV and HIV
  • Disorders of heme metabolism
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01112033

Czech Republic
Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague
Prague, Czech Republic, 128 60
Sponsors and Collaborators
Charles University, Czech Republic
Military University Hospital, Prague
General University Hospital, Prague
Institute for Clinical and Experimental Medicine
Principal Investigator: Iva Subhanova Charles University
  More Information

Responsible Party: Iva Subhanova, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University, Czech Republic Identifier: NCT01112033     History of Changes
Other Study ID Numbers: BLVRA1
Study First Received: April 23, 2010
Last Updated: August 5, 2015

Keywords provided by Iva Subhanova, Charles University, Czech Republic:
biliverdin reductase
hepatitis C
peripheral blood mononuclear cells
genetic polymorphisms

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis, Chronic
Hepatitis C, Chronic
Virus Diseases
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections processed this record on May 25, 2017